NCT02405988View on ClinicalTrials.gov

Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Drug Overdose
Interventions
DRUG

Intravenous naloxone

Administer 2,5 mL, dose intravenous naloxone 1,0 mg

DRUG

Remifentanil

Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.

Trial Locations (1)

Unknown

Department of Circulation and Medical Imaging, Trondheim

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

lead

Norwegian University of Science and Technology

OTHER

NCT02405988 - Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid | Biotech Hunter | Biotech Hunter